Lineage Cell Therapeutics

LCTX

Market cap $371M

1.48 USD

-0.01

0.67%

At close Updated Apr 10, 4:00 PM EDT

Pre-market

After hours

1.46

-0.02

1.35%

1 day

-0.67%

5 days

-3.9%

1 month

-18.23%

3 months

-15.91%

6 months

-10.84%

Year to date

-9.76%

1 year

260.98%

5 years

-38.59%

10 years

-42.86%

About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Employees: 77

Healthcare Drug Manufacturers - General